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Abstract
The growth rate of numerous cancer cell lines is regulated in part by actions of neuropeptides of the vasoac-
tive intestinal peptide (VIP) family, which also includes pituitary adenylate cyclase-activating peptide (PACAP),
glucagon, and peptide histidine/isoleucine (PHI). The aim of this work was to investigate the effect of these
peptides on the growth of the rat glioblastoma cell line C6 in vitro. We also sought to determine which binding
sites were correlated with the effects observed. Proliferation studies performed by means of a CyQuant™ assay
showed that VIP and PACAP strongly stimulated C6 cell proliferation at most of the concentrations tested,
whereas PHI increased cell proliferation only when associated with VIP. Two growth hormone–releasing factor
(GRF) derivatives and the VIP antagonist hybrid peptide neurotensin-VIP were able to inhibit VIP-induced cell
growth stimulation, even at very low concentrations. Binding experiments carried out on intact cultured C6
cells, using 125I-labeled VIP and PACAP as tracers, revealed that the effects of the peptides on cell growth were
correlated with the expression on C6 cells of polyvalent high-affinity VIP-PACAP binding sites and of a second
subtype corresponding to very high-affinity VIP-selective binding species. The latter subtype, which interacted
poorly with PACAP with a 10,000-fold lower affinity than VIP, might mediate the antagonist effects of neu-
rotensin-VIP and of both GRF derivatives on VIP-induced cell growth stimulation.
Index Entries: C6 glioblastoma; vasoactive intestinal peptide (VIP); cell growth; cancer; VIP analog; VIP
antagonist.
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Introduction
Primary central nervous system (CNS) tumors
account for approx 2% of all adult malignancies but
are responsible for approx 7% of years of life lost
owing to malignancy prior to age 70. Within adult
CNS tumors, gliomas represent 40–67% of primary
tumors. In children, 20% of all malignancies diag-
nosed before age 15 are primary CNS tumors, making
them the second most frequently diagnosed child-
hood malignancy; and it is estimated that gliomas
comprise 67% of such tumors (Bohnen et al., 1997).
Of all primary CNS malignancies, glioblastoma, a
highly malignant glioma, has the poorest progno-
sis, with the median survival limited to 7–9 mo
(Ammirati et al., 1987). Even with aggressive surgi-
cal resection followed by adjuvant therapy, such as
radiotherapy, immunotherapy, and chemotherapy,
the great majority of patients diagnosed with these
high-grade gliomas succumb to their disease. The
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prognosis for these brain tumors has not changed
significantly in the last decade, making the search
for new treatments particularly pertinent.
Neuropeptides, such as the 28-amino-acid peptide
vasoactive intestinal peptide (VIP) (Said and Mutt,
1970), fulfill an important role in the regulation of
normal neuronal development. Identified very early
in neural development, VIP appears to regulate both
proliferation and differentiation of neuronal precur-
sors in vitro and in vivo, and is also involved in
growth, differentiation, and maintenance of neurons,
among a broad range of biological activities (for
reviews, see Gozes and Brenneman, 1993; Gressens
et al., 1993; Muller et al., 1995). It has also been demon-
strated that VIP has neuroprotective properties that
influence the survival of activity-dependent neurons
in the CNS. These properties are mediated in part
through the action of glial-derived substances
released by VIP, including the activity-dependent
neurotrophic factor (ADNF), a novel neuroprotec-
tive protein that shares structural similarities to heat
shock protein 60 (hsp 60) (Brenneman and Gozes,
1996; Gozes and Brenneman, 1996, Brenneman et al.,
1998), hsp 60 itself (Bassan et al., 1998) or the
activity-dependent neurotrophic protein (ADNP),
another glial mediator of VIP-associated neuropro-
tection (Bassan et al., 1999; Offen et al., 2000). More-
over, neuropeptides have been implicated in the
progression and differentiation of malignant tumors
of the CNS and peripheral nervous system. Although
extensive data are available on the expression of these
regulatory peptides and their respective receptors in
adult nervous system tumors and in neuroblastoma
of childhood (Muller et al., 1995; Vertongen et al.,
1997; Waschek et al., 1997; Lelièvre et al., 1998b), little
is known about their occurrence and significance in
other neuronal malignancies.
These observations, together with the neuroen-
docrine nature of glioma and the identification of
VIP in gliomas (Bateman et al., 1986), provide the
basis for our hypothesis that VIP might regulate
proliferation in glioma via interaction with high-
affinity receptors.
In this study, we evaluated the ability of VIP to
modulate cell growth of the C6 rat glioblastoma cell
line (Benda et al., 1968) in vitro. We compared the
effects obtained with this peptide with those of VIP
structural analogs, Pituitary adenylate cyclase-
activating peptide-27 (PACAP-27), glucagon, and
peptide histidine/isoleucine (PHI) amide, which are
able to regulate the proliferation rate of numerous
cell lines (Pavelic and Pavelic, 1980; Moyer et al.,
1985; Vertongen et al., 1996; Lelièvre et al., 1998b).
Furthermore, we investigated whether the VIP
effects were sensitive to antagonists demonstrated
to interact with VIP binding sites, such as the D-
amino acid-substituted growth hormone releasing
factor [N-Ac-Tyr1-D-Phe2]-GRF (1–29)-NH2 (Wael-
broeck et al., 1985), [N-Ac-Tyr1-D-Arg2]-GRF (1–29)-
NH2 (Robberecht et al., 1985), and the chimeric
peptide neurotensin (6–11)-VIP (7–28) (Gozes et al.,
1995), designed to maintain the binding capacity of
the parent molecule VIP while loosing the agonistic
properties. Finally, we determined the pharmaco-
logical properties of the VIP or PACAP binding sites
that may mediate the effects observed on cell growth.
Materials and Methods
Chemicals
C6 rat glioblastoma cells (Benda et al., 1968) were
purchased from the European Collection of Animal
Cell Culture (ECACC) (Salisbury, UK). Glutamax-I
Dulbecco’s modified Eagle’s medium (DMEM)
(4.5 g/L glucose, with sodium pyruvate), penicillin-
streptomycin (10,000 U/mLpenicillin G sodium and
10,000 µg/mL streptomycin sulfate in 0.85% saline),
trypsin-EDTA solution (0.5 g/L trypsin and 0.2 g/L
EDTA in Puck’s medium), and fetal bovine serum
(FBS) were obtained from GIBCO BRL (France).
Human VIP, PACAP-27, glucagon, PHI, and [N-Ac-
Tyr1, D-Phe2]-GRF (1–29) amide were from Neosys-
tem (France). [N-Ac-Tyr1-D-Arg2]-GRF (1–29)-NH2
and neurotensin (6–11)-VIP (7–28) were from Sigma
Chemical (France).
CyQuant™ Cell proliferation assay kit was pur-
chased from Molecular Probes (USA). 125I-labeled
Na (2200 Ci/mmol) was provided by NEN Du Pont
(France). Chloramine T, sodium metabisulfite, tri-
fluoroacetic acid (TFA), bovine serum albumin
(BSA), bacitracin, and phenylmethylsulfonyl fluo-
ride (PMSF) were purchased from Sigma Chemical
(France).
Peptide Radioiodination
Vasoactive intestinal peptide or PACAP was
radioiodinated using the chloramine T method, as
described previously (Martin et al., 1986; Pineau et
al., 2001). Briefly, the reaction was initiated by the
addition of 25 µL of a 3 mg/mL chloramine T solu-
tion (prepared in a 0.2 M sodium phosphate buffer
[pH 7.6]) to 15 µL of a 10–4 M aqueous solution of
peptides mixed with 5 µL of 125I-labeled Na solution
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(~0.45 mCi). After 1 min, the reaction was stopped
with 25 µL of 2 mg/mL sodium metabisulfite pre-
pared in the same buffer. The radioiodination mix was
then passed on a C18 Sep-Pak column (Waters Asso-
ciates) using 10 mL of a 0.1% TFA aqueous solution
as eluent to discard free radioiodine. The 125I-labeled
peptides were then recovered using 2.5 mL of 8515
acetonitrile/0.1% TFA in water as eluent. They were
further purified by reverse-phase high performance
liquid chromatography (HPLC), using a 5-µm Vydac
C18 column (Interchrom, France). Elution was
conducted for 32 min with a 0–85% linear gradient of
acetonitrile in H2O/0.1% TFA. The fractions corre-
sponding to the monoiodinated form of the peptide
were dried under nitrogen and stored at –20°C.
Cell Culture
C6 rat glioblastoma cells (used between passages
7 and 25) were grown as monolayer cultures in
75-cm2 flasks (Falcon) in DMEM supplemented with
3% (v/v) FBS and penicillin-streptomycin, in a
humidified atmosphere of 95% air/5% CO2 at 37°C.
Medium was changed twice a week, and cells were
subcultured every seventh day. For subcultures, cells
were harvested in trypsin-EDTAsolution (0.05% and
0.53 mM, respectively) in Puck’s medium, for 10 min
at 37°C. Experiments were conducted with cells in
exponential growth phase.
Effect of VIP and Related Peptides 
on Cell Growth
The effects of VIP and the VIP analogs PACAP-
27, PHI, and glucagon were tested in vitro on C6
cells. Furthermore, the effects of three antagonists
demonstrated to interact with VIP receptors were
also checked on C6 cell growth:
• [N-Ac-Tyr1, D-Phe2]-GRF (1–29) amide. This antago-
nist was shown to selectively inhibit both VIP and
GRF-stimulated adenylate cyclase activities in rat pan-
creatic plasma membranes (Waelbroeck et al., 1985;
Robberecht et al., 1986) and is thus referred to here as
VIP antagonist to facilitate the reading of this article
and for the purpose of this article only.
• [N-Ac-Tyr1-D-Arg2]-GRF (1–29)-NH2. This antagonist
was able to inhibit the GRF-stimulated adenylate
cyclase in adenopituitary membranes (Robberecht et
al., 1986), and is referred to here as GRF antagonist.
• Neurotensin (6–11)-VIP (7–28). Acute administration
of this molecule resulted in the blockade of VIP-
mediated potentiation of sexual behavior in the adult
rodent and in severe microcephaly during gestation
once administered to pregnant mice (Gozes et al.,
1995).
Cells were seeded in quintuplicate at a density of
7500 cells/well in 96-well culture plates in 200 µL of
culture medium. At 24 h after plating, the medium
was removed, and fresh serum-free culture medium
containing the peptide tested at final concentrations
of 10–15–10–8 M was added. The effect induced by the
association of VIP (10–13 M) and PHI, or VIP (10–9 M)
and each antagonist, was also tested. Control cul-
tures were treated with medium without any pep-
tide addition or with VIP alone (10–9 M) in the case
of the antagonist assay. The cells were then further
incubated for 3 d. At the end of the treatment,
medium was removed and the cells were frozen until
the cell-counting assay. Cell growth was assessed by
using the CyQuant cell proliferation assay kit, based
on the use of the green fluorescent CyQuant GR dye,
which exhibits strong fluorescence enhancement
when bound to cellular nucleic acids. Frozen cells
were simply thawed and lysed by addition of a buffer
containing the CyQuant GR dye (200 µL/well)
at room temperature and protection from light.
Fluorescence was then measured directly using a
fluorescence microplate reader (Fluorocount
Packard) with filters appropriate for 480-nm excita-
tion and 520-nm emission maxima. Data were
expressed in percentage of gain or loss of cells com-
pared to control, set to 0%.
Binding Studies
The receptor binding affinity of VIP, VIP-related
peptides, and antagonists in C6 rat glioblastoma cells
was measured in displacement experiments based
on competitive inhibition of radiolabeled peptide
binding using various concentrations of unlabeled
peptide, as previously reported (Muller et al., 1989).
Briefly, cells (200,000 cells/well) were seeded in
24-well plates and cultured for 3 d. Culture medium
was then removed, and the cells were incubated for
2 h at 13°C, in the presence of 50 pM 125I-labeled, VIP
or PACAPand increasing concentrations of VIP, PHI,
PACAP-27, or antagonists in DMEM/150 mM
HEPES, pH 7.4, containing 1% BSA, 0.1% bacitracin,
and 150 µM PMSF. Binding reactions were stopped
by cooling the dishes on ice. Cells were rinsed three
times with 1 mL cold phosphate-buffered saline
(PBS)/0.1% BSA and lysed with 500 µL of 0.5 M
NaOH. Radioactivity of the cell lysates was quanti-
fied with a Cobra II Auto-Gamma Counting System
(Packard, Downers Grove, IL). Specific binding was
calculated as the difference between the mean deter-
mination of total binding and binding in the pres-
ence of excess native VIP or PACAP-27 (10–7 M). The
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fitting of the data by nonlinear regression was com-
puted according to a Hill equation using Graphpad™
Prism software (San Diego, CA) in order to deter-
mine two parameters: (1) the concentration of unla-
beled peptide giving half-maximal inhibition of
the radiotracer binding (IC50); and (2) the total num-
ber of sites/cell interacting with a given radio-
tracer (Bmax).
Statistical Analysis
Results are expressed as means ±S.E.M., and sta-
tistical significance was determined by one-way
analysis of variance (ANOVA), followed by Bonfer-
roni’s test. Differences were considered significant
when p < 0.05, very significant when p < 0.01, and
highly significant when p< 0.001. Data were the mean-
ing of three independent quadruplicate binding
experiments or quintuplicate cell growth experiments.
Results
Effect of VIP and Related Peptides 
on Cell Growth
Generally, the cell proliferation assay demon-
strated that VIP and related peptides were potent
stimulators of C6 cell proliferation (Fig. 1A). VIP
exerted a concentration-dependent strong prolifer-
ative effect, by up to 69 ± 9%. This response was
biphasic over a first concentration range from 10–15
to 10–13 M and a second range from 10–11 to 10–8 M,
whereas no significant stimulation was observed at
Fig. 1. Effect of increasing concentrations of exogenous VIP and VIP-related peptides (PACAP-27, PHI, and glucagon)
on the proliferation of C6 cells in culture, each acting alone (A). (B) Combined action of VIP (10–13 M), together with
increasing concentrations of PHI. Cell growth was expressed as the percentage of variation of cell number compared to
cell number observed without treatment (control) (0%). Data are the mean ± S.E.M. of three independent experiments,
each performed in quintuplicate. (*) p < 0.05 vs untreated cells.
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the concentration of 10–12 M. Though slightly less
potent than VIP, PACAP-27 also induced a signifi-
cant dose-dependent stimulation (up to 68 ± 10%)
of cell growth, starting at the lowest concentrations.
This response was monophasic: Limited effects were
observed for low concentrations ranging from 1 fM
to 1 pM concentrations, whereas a dose-dependent
increased cell proliferation (with a half-maximal
effect in the nanomolar range) was observed for con-
centrations ranging from 1 pM to 10 nM. On the other
hand, addition of glucagon induced limited though
significant cell growth inhibition at the lowest con-
centrations (–15 ± 4% at 10–14 M); poor effects on cell
proliferation were then observed for higher values,
except for the highest doses tested (~50% stimula-
tion for a 10 nM treatment). The VIP analog PHI
alone also stimulated cell growth poorly (Fig. 1A),
whereas in combination with VIP (10–13 M), this pep-
tide induced a strong and sensitive stimulation of
cell proliferation for all concentrations tested, with
a maximum increase of 124 ± 33% occurring at
10–10 M. These effects were always higher than those
observed with either VIP or PHI alone (Fig. 1B).
Effects of antagonists on cell growth were also
studied for concentrations starting from 0.1 pM. To
facilitate reading, antagonists [N-Ac-Tyr1, D-Phe2]-
GRF (1–29) amide, [N-Ac-Tyr1, D-Arg2]-GRF (1–29)-
NH2, neurotensin (6–11)-VIP (7–28) will be
designated, respectively, as VIP antagonist, GRF
antagonist, and neurotensin-VIP, for the purpose of
this article only.
All of the antagonists tested generally induced a
dose-dependent cell proliferation increase, com-
pared with the growth of untreated cells (Fig. 2A).
Asignificant stimulation of cell growth was observed
for concentrations starting from 10–13 M for the VIP
antagonist and neurotensin-VIP and from 10–11 M
for the GRF antagonist.
On the other hand, the cotreatment of 10–9 M VIP
with increasing concentrations of each of the three
antagonists generally resulted in a significant
decrease of the proliferation induced by 10–9 M VIP
alone (corresponding to ~50% increase of cell
growth), the extent of which varied depending on
the antagonist utilized (Fig. 2B). A combination of
1 nM VIP, together with neurotensin-VIP or the GRF
antagonist, did not cause any significant stimulation
of cell proliferation for concentrations ranging from
1 fM to 0.1 nM. Then a weak stimulation of the pro-
liferation was observed for higher concentrations
(1 and 10 nM) of these antagonists (up to ~25%),
together with 1 nM VIP, however, to a much lower
extent than that observed with 1 nM VIP alone (50%
stimulation, as indicated above). In contrast, the VIP
antagonist never readily suppressed the 1 nM VIP-
induced stimulation of cell proliferation, despite the
concentration tested. However, this antagonist uti-
lized together with 1 nM VIP triggered a reduced
stimulation of cell proliferation (with a maximal
increase of 26 ± 6% at 10–10 M), in comparison with
1 nM VIP acting alone (50% stimulation).
Binding Studies
Data from 125I-labeled VIP binding displacement
experiments (Fig. 3A) suggested the expression of
two different binding sites for VIP in C6 cells: very
high-affinity binding sites (46% of the total binding
sites [IC50: 1.5 × 10–14 ± 0.5 × 10–14 M]) and high-
affinity sites (IC50: 1.7 × 10–10 ± 0.3 × 10–10 M). The
curve corresponding to 125I-labeled VIP displace-
ment by increasing concentrations of PACAP fitted
a one-site equation well and indicated a high-
affinity interaction of PACAP-27 on 125I-labeled VIP
binding sites in C6 cells (IC50: 1.1 × 10–8 ± 0.1 × 10–8 M
for PACAP-27). No displacement of 125I-labeled VIP
binding by PHI was observed.
Experiments of competitive displacement of 125I-
labeled PACAP binding (Fig. 3B) revealed that unla-
beled VIP and PACAP-27, but not PHI, were able to
interact with 125I-labeled PACAP binding sites, with
a similar high affinity (IC50: 1.2 × 10–9 ± 0.1 × 10–9 M
for VIP and 7.1 × 10–9 ± 0.1 × 10–9 M for PACAP-27).
The binding of 125I-labeled PACAP on C6 cells was
entirely displaced by VIP.
Data from 125I-labeled VIP binding displacement
experiments by the antagonists (Fig. 4) also fitted a
one-site equation well. However, all three antago-
nists interacted only with the portion of the
125I-labeled VIP binding displacement curve corre-
sponding to very high-affinity binding sites. In fact,
very low IC50 values were observed for all three
antagonists: IC50 = 1.5 × 10–13 ± 0.3 × 10–13 M for neu-
rotensin-VIP; IC50 = 1.2 × 10–13 ± 0.2 × 10–13 M for the
GRF antagonist; and IC50 = 1.7 × 10–13 ± 0.4 × 10–13 M
for the VIP antagonist.
Discussion
The data reported here demonstrate that VIP, PHI,
PACAP-27, and glucagon efficiently modulated the
proliferation of rat glioblastoma C6 cells, each pep-
tide (or peptide combination) displaying a distinct
behavior in this regard. A strong stimulation was
obtained with VIP and PACAP-27, but only VIP
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appeared particularly potent at very low concen-
trations, in the femtomolar range. Glucagon, on the
other hand, inhibited proliferation at low concen-
trations while it stimulated proliferation only for
higher doses (10–9–10–8 M). The VIP analog PHI,
acting alone, exerted no significant or very modest
effects in the range of concentrations utilized but
appeared to be efficient to potentialize the action of
0.1 pM VIP on cell proliferation. This observation
indicates that distinct binding sites interacting selec-
tively with PHI, but not with VIP, might mediate the
potentialization exerted by PHI on VIP-induced
stimulation of cell proliferation. However, the action
of PHI acting alone on its selective binding sites
might not be able to induce any growth stimula-
tion effect.
A particularly intriguing question was the bipha-
sic proliferative response to VIP for concentrations
ranging from 10–15 to 10–13 M and from 10–11 to
10–8 M, whereas 10–12 M VIP triggered poor effects.
Such data indicate that different subtypes of recep-
tors might mediate this complex effect of VIP. Bipha-
sic responses to peptides of the VIPfamily have been
reported previously in other systems. For example,
VIP at 50 pM stimulated proliferation of cultured
retinal-pigmented epithelium cells, whereas higher
concentrations inhibited proliferation (Koh, 1991).
In addition, biphasic action of VIP on cell growth
Fig. 2. Effect of three exogenous VIP receptor antagonists on the proliferation of C6 cells in culture: neurotensin-VIP;
GRF antagonist; and VIP antagonist. Cell growth was expressed as the percentage of variation of cell number after treat-
ment with VIP receptor antagonists, compared to cell number observed without treatment (control) (0%) (A) (*) p < 0.05
vs untreated cells), or the percentage of variation of cell number after treatment with VIP receptor antagonists together
with VIP 10–9 M, compared to cell number observed without treatment (control) (0%) (B) (*) p < 0.05 vs untreated cells).
Data are the mean ± S.E.M. of three independent experiments, each performed in quintuplicate (n = 15).
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has been reported for Lo-Vo colonic carcinoma cells
(Yu et al., 1992) and T98G glioblastoma cells (Ver-
tongen et al., 1996). Asimilar effect was also described
by Lelièvre et al. (1998b) on Neuro2a neuroblastoma
cells after stimulation by PACAP, and by Chneiweiss
et al. (1986) in the case of stimulation exerted by VIP
on adenylate cyclase in glial cells. Furthermore, VIP
appears to be inhibitory or stimulatory in function
of the model studied. It stimulated cell proliferation
in mouse astroglial cells (Brenneman et al., 1990),
whereas it inhibited proliferation in others, like
the human neuroblastoma IMR 32 (O’Dorisio et al.,
1992) and the T98G glioblastoma (Vertongen et al.,
1996). A lipophilic VIP analog, stearyl-Nleu(17)-
neurotensin (6–11)-VIP(7–28), enhanced the antipro-
liferative effect of chemotherapeutic agents, such as
doxorubicin, cisplatine, and vinorelbine, on
advanced solid tumors, such as nonsmall cell lung
carcinoma, colon carcinoma, or prostate carcinoma
(Gelber et al., 2001).
In our studies, proliferative effects obtained with
PACAP-27 treatments were quite modest for low
concentrations of the peptide, ranging from 10–15 to
10–13 M. Then a dose-dependent increased cell growth
was observed for higher concentrations for which
PACAP-27 was about as potent as VIP to stimulate
cell proliferation. Hence, PACAP-27 does not repro-
duce the effect of extremely low concentrations of
Fig. 3. Competitive displacement of 125I-labeled VIP binding (A) and 125I-labeled PACAP-27 binding (B) by unlabeled
peptides: VIP, PACAP-27, and PHI. Data represent the percentage of specific binding compared to control (100%, in the
absence of any competitor peptide). Data are the mean ± S.E.M. of three independent experiments, each performed in
quadruplicate. Total specific binding: 493 cpm (VIP); 533 cpm (PACAP-27).
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VIP on cell proliferation, indicating that this VIP
analog might not be able to activate the subset of
VIP binding sites involved in this effect. Effects of
PACAP-27 have been demonstrated previously by
Waschek et al (2000) on the proliferation of the mouse
neuroblastoma tumor cell line Neuro2a at sub-
nanomolar doses (>10% increase in thymidine incor-
poration occurring at 10–10 M), whereas PACAP was
shown by Vertongen et al (1996) to inhibit human
glioblastoma T98G cell proliferation.
Of particular interest was the significant antipro-
liferative action of glucagon, observed only for con-
centrations lower than 10–12 M. Such effects have not
been mentioned before for this peptide. However it
has been shown by Pavelic and Pavelic (1980) that
glucagon retards the growth of mammary aplasic
carcinoma in vivo and prolongs the mean survival
time of the animals treated. It should thus be inter-
esting to analyze in C6 cells the potential expression
of glucagon receptors that might mediate the
modulatory action of glucagon on VIP-induced cell
proliferation.
Because exposure to VIP increased cell prolifera-
tion, we also examined in this study the effects of
treatments with antagonists on the growth of C6
cells, alone or together with a given 1 nM VIP con-
centration that triggered a maximal effect on prolif-
eration after a 3-d treatment. Exposure of C6 cells to
neurotensin-VIP, GRF antagonist, or VIP antagonist
acting alone; respectively, resulted in a dose-
dependent increase of cell proliferation. The order
of efficiency of these peptide derivatives to stimu-
late cell growth was neurotensin-VIP > VIP antago-
nist > GRF antagonist.
In the presence of 10–9 M VIP, all three antagonists
very significantly reduced cell growth compared to
the effects obtained with 1 nM VIP alone, despite the
antagonist concentration used. For concentrations
ranging from 10–15 M to 10–11 M, the neurotensin-VIP
and the GRF antagonist completely blocked the
action of VIP, thus resuming the same cell growth as
the control cells that received no peptide treatment
at all. Treatment with the lowest concentrations of
neurotensin-VIP even resulted in a reduction in cell
number, compared to untreated control cells, with a
maximal reduction (about –20%) occurring for the
10–15 M antagonist. The order of efficiency of these
peptide derivatives to inhibit cell growth stimulated
by 1 nM VIP was neurotensin-VIP > GRF antagonist
> VIP antagonist.
Interestingly, the biphasic dose-response curve
observed by cotreating cells with the VIP antago-
nist, together with 1 nM VIP, was very close to the
shape of the dose-response curve obtained with
increasing concentrations of VIP alone, except that
the amplitude of the response was globally reduced.
Such an inhibition of VIP effect by these mole-
cules has been described previously (Gozes et al,
1995). Acute administration of neurotensin-VIP
resulted in blockade of VIP-mediated potentiation
of sexual behavior in the adult rodent. During ges-
tation, severe microcephaly was induced by acute
administration of neurotensin-VIPto pregnant mice.
This antagonist appears to be a competitive blocker
Fig. 4. Competitive displacement of 125I-labeled VIP binding by unlabeled VIP antagonists, neurotensin-VIP, GRF antag-
onist, and VIP antagonist. Data represent the percentage of specific binding compared to control (100%, in the absence
of any competitor peptide). Data are the mean ± S.E.M. of three independent experiments, each performed in quadru-
plicate. Total specific binding: 493 cpm (VIP).
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for both VIP-mediated increase of cAMP production
or VIP-associated maintenance of neuronal survival
in spinal cord cultures (Gozes et al., 1991). The VIP
antagonist was shown to selectively inhibit both VIP
and GRF-stimulated adenylate cyclase activities in
rat pancreatic plasma membranes (Waelbroeck et al.,
1985; Robberecht et al., 1986). The GRF antagonist
was able to inhibit the GRF-stimulated adenylate
cyclase in adenopituitary membranes (Robberecht
et al., 1986).
The observations of the differential effects of pep-
tides (or peptide combinations) considered in the
present studies suggested the hypothesis that mul-
tiple binding sites for these peptides were expressed
in C6 cells, which led us to characterize the phar-
macological profiles of the 125I-labeled VIP and
125I-labeled PACAP-27 binding sites expressed in C6
cells. These parameters have not been characterized
so far on C6 cells. Data from experiments of inhibi-
tion of the binding of 125I-labeled VIP or 125I-labeled
PACAP-27 radiotracers by unlabeled VIP, PACAP-
27, or PHI were consistent with the expression of
two different VIP and PACAP binding species:
• VIP-selective very high-affinity binding sites with an
uncommonly low IC50 value in the femtomolar range
(estimated to be 48% of the total VIP binding species).
This fraction of sites displays a 105-fold lower IC50
value for VIP than for PACAP.
• Bivalent high-affinity VIP/PACAPbinding sites with
similar IC50 values for both peptides are in the
nanomolar range.
In all experiments conducted, PHI never inhib-
ited the binding of 125I-VIPand 125I-labeled PACAP-
27, clearly indicating that potential effects of this
peptide on C6 cells could not result in the interac-
tion of this peptide with the VIPand PACAP-27 bind-
ing species expressed in this cell line.
Hence, C6 cells express binding species that could
correspond to the VIP/PACAP receptors, the so-
called VPAC1 and VPAC2 molecular species (using
the International Union of Pharmacology nomen-
clature), which were extensively characterized, in
terms of sequence, pharmacological profile, tissue
expression, and associated signaling pathways in
several tissues and cell lines. The expression of
VPAC2 receptors involved in antiproliferative effects
of VIP or PACAP has been demonstrated in glial
tumors and in the human glioblastoma cell line T98G
(Vertongen et al., 1996). However, PACAP-
preferring high-affinity binding sites of the PAC1
subtype, which binds PACAP more exclusively with
modest affinity for VIP and practically no interac-
tion with PHI, were demonstrated to be expressed
in surgical specimens of human glioblastomas and
in several types of gliomas (Robberecht et al., 1994;
Vertongen et al., 1996).
However, the most uncommon data obtained in
the present studies was the finding of VIP-selective
very high-affinity binding sites. The expression of
VIP-selective high-affinity binding sites in glial cells
(Brenneman et al., 1987; Gozes et al., 1991), in the
human glioma cell line U-343 Mgcl 2:6 (Nielsen et
al., 1990), and in the human glioblastoma XF-498L
(Fabry et al., 2000) has been reported previously, and
it has been demonstrated that the neuroprotective
effects of VIP or PACAP could be observed for very
low concentrations, close to the femtomolar range
(Kong et al., 1999; Offen et al., 2000). However, data
from the present studies are, as far as we know, an
unprecedented characterization of VIP-selective
binding sites with such a very high affinity, in the
femtomolar range. The affinity of these very high-
affinity sites for VIP is about 10,000-fold greater than
that of the “traditional” high-affinity receptors
VPAC1 or VPAC2, suggesting that VIP could act in
C6 cells at extremely low concentrations. As a matter
of fact, the remarkably high affinity of these sites,
strongly suggests that they are the candidate recep-
tors to induce the increased C6 cell proliferation
observed in the present study for concentrations
lower than 10–12 M VIP. The interaction of VIP with
traditional high-affinity binding sites, correspond-
ing to VPAC1 or VPAC2 receptors, could account for
the VIP-induced growth stimulation observed for
concentrations higher than 10–12 M. Expression of
both subtypes of binding sites in the C6 cell line thus
explains the biphasic proliferation response
observed when these cells are treated with increas-
ing concentrations of VIP.
Another prominent property of the very high-
affinity VIP binding sites expressed in C6 cells is
their selective interaction with the three antagonists
evaluated in our studies. In fact, these components
only partially inhibited the 125I-labeled VIP inter-
action in C6 cells, affecting only the portion of the
displacement curve corresponding to the very high-
affinity VIP binding sites. The IC50 values calculated
for these antagonists in the femtomolar range con-
firm that these molecules behave like very selective
and very high-affinity ligands for a fraction of the
125I-labeled VIP binding sites expressed in C6 cells.
It has been long reported that GRF, besides its high-
affinity interaction with pituitary GRF receptors
(Robberecht et al., 1985), also interacted with VIP
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receptors (Laburthe et al., 1983; Waelbroeck et al.,
1985), probably with a higher affinity for VPAC1
than for VPAC2 receptors (Robberecht et al., 1996).
Conversely, GRF had only a negligible interaction
with the rat PACAP-preferring receptors (Gourlet et
al., 1997). Primary reports on the VIPantagonist con-
sidered in this study, or on neurotensin-VIP, indi-
cated that these components generally behave like
low-affinity ligands (in the micromolar range) of the
VIP binding sites of peripheral cells from different
tissue origins, such as small-cell lung carcinomas or
human neuroblastomas (Moody et al., 1993; Lilling
et al., 1994). Other investigators have found that neu-
rotensin-VIP inhibited 125I-labeled VIP binding to
cells from cerebral cortex, hippocampus, or spinal
cord with Ki values in the picomolar or nanomolar
range, respectively, for high- and low-affinity bind-
ing sites. The antagonizing effects of neurotensin-
VIP occurred on neuronal cell with an IC50 value of
30 pM (Gozes et al., 1991). It is worth noting that
antiproliferative effects of neurotensin-VIP in vitro
and in vivo (on xenografts in nude mice) have also
been related to the antagonist properties of this
hybrid peptide toward PACAP-selective receptor
PAC1 (Sharma et al., 2001). Taken together, these
data suggest that very high-affinity VIPbinding sites
such as those observed in this study might not be
frequent in peripheral tissues but might be repre-
sented much more in the CNS, possibly in glial cells,
mediating typical effects of extremely low concen-
trations of VIPor other related peptides in this tissue.
The three antagonists considered in the present study
appear to behave like very selective ligands, able to
counteract effects of very low concentrations of VIP
on cell growth, possibly mediated through the
unusual very high-affinity binding sites. However,
higher concentrations of these antagonists also exert
potent agonist properties on C6 cell proliferation
when acting alone. An explanation for this peculiar
phenomenon could be that VIP and the antagonists
mutually compete with each other for their interac-
tion with—at least partially—overlapping binding
domains, thus embedding the efficient activation of
their common receptors. A similar observation was
reported previously by our group in the colonic car-
cinoma cell line SW403 treated by VIP, PACAP, or
both peptides (Lelièvre et al., 1998a): We demonstrated
that combined treatments with both agonists were
less efficient to regulate cGMPproduction than treat-
ments with individual peptides. Such data indicate
that combining two potent peptide agonists could
result in pseudoantagonist effects, possibly through
a competition of both peptides at the level of common
binding sites, resulting in a decreased efficacy of the
combined peptides to activate the receptors.
In conclusion, we demonstrated that VIP and the
related neuropeptide PACAP-27 stimulated the pro-
liferation of C6 rat glioblastoma cells, whereas antag-
onists inhibited the growth effects of VIPat extremely
low concentrations, probably acting through an
unusual subclass of very high-affinity VIP binding
sites, displaying a Kd value in the femtomolar range.
Hence, we propose that these antagonists, neu-
rotensin-VIP and the two GRF derivatives, should be
considered as invaluable tools to further character-
ize the pharmacological, molecular, and functional
properties of the very high-affinity selective VIP
receptors expressed in the C6 glioblastoma cell line.
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